CASI Pharmaceuticals files Form 25 to remove Nasdaq listing

CASI Pharmaceuticals, Inc. notified Nasdaq of the removal of its Ordinary Shares from listing and/or registration under Section 12(b) via a Form 25 submission.

Rhea-AI Filing Summary

CASI Pharmaceuticals, Inc. notified Nasdaq of the removal of its Ordinary Shares from listing and/or registration under Section 12(b) via a Form 25 submission. The exchange certified compliance with 17 CFR 240.12d2-2 and the issuer certified compliance with exchange rules.

Insights

Exchange Compliance Analyst

Form 25 documents a Nasdaq delisting/withdrawal process for CASI Pharmaceuticals.

Nasdaq submitted a Form 25 (Commission File Number 001-41666) indicating it has "reasonable grounds" to file for removal and that it complied with the procedures in 17 CFR 240.12d2-2. The filing identifies the security as Ordinary Shares.

The action is administrative: timing, reasons for delisting, and any subsequent trading or transfer arrangements are not detailed in the excerpt. Further filings or exchange notices would disclose effective dates or operational impacts.

Key Figures

Commission File Number: 001-41666 Form expiration note: March 31, 2018 Telephone number: +1 301 217-9858 +1 more

4 metrics

Commission File Number 001-41666 Form 25 cover reference

Form expiration note March 31, 2018 Expires line on form copy

Telephone number +1 301 217-9858 Issuer principal executive offices contact

Cited regulation 17 CFR 240.12d2-2 Exchange compliance and delisting rules

Key Terms

Form 25, 17 CFR 240.12d2-2, Removal from listing and/or registration

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b)"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

Removal from listing and/or registration financial

"NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does CASIF's Form 25 filing mean for shareholders?

It notifies that CASI Pharmaceuticals' Ordinary Shares are being removed from Nasdaq listing. The filing certifies compliance with 17 CFR 240.12d2-2 and exchange rules; operational details or next steps are not included in the excerpt.

Who filed the delisting notification for CASIF?

Nasdaq Stock Market LLC filed the Form 25 on behalf of the exchange. The filing is certified by an exchange official, identified as Aravind Menon, Hearings Advisor, with Commission File Number 001-41666.

Which securities class is affected in the CASIF Form 25?

The filing identifies the affected class as Ordinary Shares. The submission references compliance with 17 CFR 240.12d2-2 related to removal from listing and/or withdrawal of registration.

Does the Form 25 excerpt state when the removal becomes effective?

The excerpt does not state an effective removal date. It includes an expiration note of March 31, 2018 on the form copy, but no explicit effective delisting date is provided in the visible text.

Where is CASI Pharmaceuticals' principal executive office listed in the filing?

The address is given as 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Beijing, CHINA 100025, and a telephone number of +1 301 217-9858 appears in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 01:45 PM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-41666

Issuer:	CASI Pharmaceuticals, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1701-1702, China Central Office Tower 1
	No. 81 Jianguo Road
	Beijing	CHINA	100025
Telephone number:					+1 301 217-9858

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Ordinary Shares

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-06-23	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.